Pennant Group

PNTG · NASDAQ

$41.48+$0.82 (+2.02%)TodayMarket closed ·
Prev close $40.66

About PNTG

The Pennant Group, Inc. is a holding company, which engages in the provision of healthcare services to patients of all ages. The company is headquartered in Eagle, Idaho and currently employs 9,700 full-time employees. The company went IPO on 2019-09-19. Each of these businesses is operated by a separate, independent operating subsidiary. Its segments include home health and hospice services, and senior living services. Its home health and hospice services segment includes its home health, hospice and home care businesses. Its home health services provide care after surgery or when illness or health conditions require additional assistance. Its senior living services segment includes the operation of assisted living, independent living and memory care communities. Its independent living communities are designed for active individuals or couples.

Employees
9,700
Headquarters
Eagle, Idaho
Listed
Sep 19, 2019
Sector
Health Care
Industry
Health Care Providers & Services

PNTG key statistics

Market cap
1.45B
Price-earnings ratio
44.68
Dividend yield
—
Average volume
310.52K
Volume
287.12K
Open price
$40.78
High today
$41.88
Low today
$40.78
52 Week high
$42.74
52 Week low
$22.26

Pennant Group (PNTG) at a glance

Pennant Group (PNTG) last traded at $41.48, with a market cap of 1.45B and a price-to-earnings ratio of 44.68.

Today the stock has traded between $40.78 and $41.88. The current price is 1.7% above the day's low and 1.0% below its high.

Volume so far is 287.12K shares, in line with the average of 310.52K shares a day.

Over the past year Pennant Group has ranged from $22.26 to $42.74, and now sits 94% of the way up that range.

Pennant Group met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $0.36 per share against an estimate of $0.3366.

The average analyst price target is $47.60, 14.8% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $47.60
Low
$44.44
Now
$41.48
High
$51.45

PNTG earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 7.0% on average.

  1. Q3 FY24: reported $0.26 per share against an estimate of $0.2346
  2. Q4 FY24: reported $0.24 per share against an estimate of $0.2448
  3. Q1 FY25: reported $0.27 per share against an estimate of $0.2423
  4. Q2 FY25: reported $0.27 per share against an estimate of $0.2754
  5. Q3 FY25: reported $0.30 per share against an estimate of $0.2839
  6. Q4 FY25: reported $0.34 per share against an estimate of $0.322
  7. Q1 FY26: reported $0.32 per share against an estimate of $0.3147
  8. Q2 FY26: reported $0.36 per share against an estimate of $0.3366

PNTG news

  • Forecasting The Future: 4 Analyst Projections For Pennant Gr

  • A Glimpse Into The Expert Outlook On Pennant Gr Through 4 Analysts

  • Forecasting The Future: 4 Analyst Projections For Pennant Gr

  • Breaking Down Pennant Gr: 4 Analysts Share Their Views

  • What Analysts Are Saying About Pennant Gr Stock

  • Press releaseBusiness Wire

    CareTrust REIT Positions for Continued Growth with New $500 Million Term Loan and New Hires

  • A Glimpse Into The Expert Outlook On Pennant Gr Through 4 Analysts

  • Assessing Pennant Gr: Insights From 6 Financial Analysts

Similar companies

Companies in the same industry as Pennant Group

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.